Record year for Swiss biotech industry
Driven by the corona crisis, the Swiss biotech ecosystem is thriving as never before. This is evidenced by the Swiss Biotech Report from EY, the...
COVID-19 med APN01 selected to be tested in ACTIV study
Apeiron Biologics announced that an expert panel has selected its clinical COVID-19 treatment APN01 to participate in the Phase II US ACTIV-4d RAAS...
Swiss Oculis SA raises $57m in Series C
The financing was co-led by new investors BVCF Management and Hyfinity Investments, with VI Partners and Wille AG joining the company’s existing...
Step Pharma SAS raises €35m in Series B
The financing round of the French drug development company was co-led by new investors Hadean Ventures and Sunstone Life Science Ventures with...
Targeting SARS-CoV-2 differently
Using X-ray crystallography, Sebastian Günther and colleagues screened more than 5,000 drug compounds, identified seven compounds that bind to Mpro,...
PCR-test reveals risk of genotoxity of genome editing
The new method called single targeted linker-mediated PCR sequencing (CAST-Seq), developed at University Hospital Freiburg, Germany, is set to become...
Senti Bio and Bluerock ink Regmed collaboration
Under the R&D and licence option agreement, Bluerock will apply Senti Bio’s gene circuit technology to create engineered regmed cell therapies...